drugset / Trial / NCT03880656
BM-MNCs for Lower Extremity Compartment Syndrome Injury
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1 study to assess safety and tolerability of intramuscular administration of two different doses of autologous bone marrow mononuclear cells (BM-MNCs) for treatment of lower extremity injury complicated by compartment syndrome injury.
Timeline
- Start
- 2019-12-04
- Primary completion
- 2025-12
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous bone marrow mononuclear cells | Cell therapy | 350000 unknown | Intramuscular |
| Subject | autologous bone marrow mononuclear cells | Cell therapy | 700000 unknown | Intramuscular |